Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roberts Laboratories Inc.

Latest From Roberts Laboratories Inc.

Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

Hits, Misses & Key Firsts For EMA’s PRIME Scheme

The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.

Europe Research & Development

Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Companies Clinical Trials

J.P. Morgan Day 3: First TCR Therapy On The Horizon, Asian Firms Make Their Mark

Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies. 

Companies Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register